(-)-epigallocatechin 3-gallate/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases tumour necrosis factor alpha concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“After treatment with EGCG, IL-2 and IFN-γ levels were significantly increased (P<0.05 vs. asthma group); IL-4, IL-6 and TNF-α levels were significantly diminished (P<0.05 vs. asthma group).”
Quoted verbatim from Epigallocatechin gallate improves airway inflammation through TGF‑β1 signaling pathway in asthmatic mice.. - Study
- animal · not in humans
- Duration
- 7 days
- Dose
- 10 or 20 mg/kg/day EGCG by caudal vein injection; the sentence does not say which EGCG group
- Population
- Male Balb/c mice with ovalbumin-induced asthma, serum cytokines by cytometric bead array, EGCG-treated groups versus untreated asthma model group
Epigallocatechin gallate improves airway inflammation through TGF‑β1 signaling pathway in asthmatic mice.2018PMID:29916550Permalink
Keep reading
- Everything the graph holds on (-)-epigallocatechin 3-gallate
- Every compound studied against Tumour necrosis factor alpha concentration
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M454XFEKFETV3VZXKMMKMQ2H